It hasn't been a great afternoon session for Teva Pharmaceutical Industries investors, who have watched their shares sink by -1.4% to a price of $7.54. Some of you might be wondering if it's time to buy the dip. If you are considering this, make sure to check the company's fundamentals first to determine if the shares are fairly valued at today's prices.
Teva Pharmaceutical Industries Has an Attractive P/B Ratio but a Worrisome P/E Ratio:
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) ratio of 4.16. In contrast, Teva Pharmaceutical Industries has a trailing 12 month P/E ratio of -5.2 and a P/B ratio of 1.07.
Teva Pharmaceutical Industries's PEG ratio is 2.09, which shows that the stock is probably overvalued in terms of its estimated growth. For reference, a PEG ratio near or below 1 is a potential signal that a company is undervalued.
Exceptional Profitability Overshadowed by Excessive Leverage:
2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
---|---|---|---|---|
Revenue (MM) | $16,887 | $16,658 | $15,878 | $14,925 |
Gross Margins | 44.6% | 46.4% | 47.8% | 46.7% |
Operating Margins | 16.1% | 18.4% | 19.5% | 18.0% |
Net Margins | -5.92% | -23.95% | 2.63% | -15.77% |
Net Income (MM) | -$999 | -$3,990 | $417 | -$2,353 |
Net Interest Expense (MM) | -822 | -963 | -1,058 | -966 |
Net Interest Expense (MM) | -$822 | -$963 | -$1,058 | -$966 |
Depreciation & Amort. (MM) | -$416 | -$1,557 | -$1,330 | -$1,308 |
Earnings Per Share | -$0.91 | -$3.64 | $0.38 | -$1.44 |
EPS Growth | n/a | -300.0% | 110.44% | -478.95% |
Diluted Shares (MM) | 1,091 | 1,095 | 1,107 | 1,120 |
Free Cash Flow (MM) | $419 | $638 | $236 | $1,042 |
Capital Expenditures (MM) | -$119 | -$578 | -$562 | -$548 |
Net Current Assets (MM) | -$28,943 | -$26,574 | -$23,849 | -$23,264 |
Current Ratio | 0.98 | 0.99 | 1.14 | 1.05 |
Long Term Debt (MM) | $24,562 | $22,731 | $21,617 | $19,103 |
LT Debt to Equity | 1.76 | 2.27 | 2.1 | 2.42 |
Teva Pharmaceutical Industries has stable revenues and increasing reinvestment in the business, strong margins with a stable trend, and generally positive cash flows. However, Teva Pharmaceutical Industries has slimmer gross margins than its peers, declining EPS growth, and high levels of debt.